201 related articles for article (PubMed ID: 17624533)
21. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].
Bourguet P; Planchamp F; Montravers F; Vincendeau S; Courbon F; Edeline V; Helal BO; Rossi D; Villers A; ; ; ; ; ; ; ;
Bull Cancer; 2006 Dec; 93(12):1228-32. PubMed ID: 17191352
[No Abstract] [Full Text] [Related]
22. PET imaging in the management of tumors of testis and ovary: current thinking and future directions.
Basu S; Rubello D
Minerva Endocrinol; 2008 Sep; 33(3):229-56. PubMed ID: 18846028
[TBL] [Abstract][Full Text] [Related]
23. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
24. Prospective head-to-head comparison of
Eiber M; Rauscher I; Souvatzoglou M; Maurer T; Schwaiger M; Holzapfel K; Beer AJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2179-2188. PubMed ID: 28803358
[TBL] [Abstract][Full Text] [Related]
25. FDG in Urologic Malignancies.
Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
[TBL] [Abstract][Full Text] [Related]
26. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose.
Heicappell R; Müller-Mattheis V; Reinhardt M; Vosberg H; Gerharz CD; Müller-Gärtner H; Ackermann R
Eur Urol; 1999 Dec; 36(6):582-7. PubMed ID: 10559612
[TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.
Bouchelouche K; Oehr P
J Urol; 2008 Jan; 179(1):34-45. PubMed ID: 17997425
[TBL] [Abstract][Full Text] [Related]
28. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
Bourguet P; Planchamp F; Montravers F; Vincendeau S; ;
Prog Urol; 2007 Apr; 17(2):172-5. PubMed ID: 17489312
[No Abstract] [Full Text] [Related]
29. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
[TBL] [Abstract][Full Text] [Related]
30. [Visualization of prostate cancer with 11C-choline positron emission tomography (PET): localization of primary and recurrent prostate cancer].
Kanda T; Nakagomi K; Goto S; Torizuka T
Hinyokika Kiyo; 2008 May; 54(5):325-32. PubMed ID: 18546855
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
32. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
34. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
35. [Accuracy of computed tomography in urological tumour diagnosis (author's transl)].
Latal D; Kuber W; Imhof H; Küster W
Wien Klin Wochenschr; 1981 Jun; 93(13):415-20. PubMed ID: 7269622
[TBL] [Abstract][Full Text] [Related]
36. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
37. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
38. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
39. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.
Treglia G; Giovannini E; Di Franco D; Calcagni ML; Rufini V; Picchio M; Giordano A
Ann Nucl Med; 2012 Jul; 26(6):451-61. PubMed ID: 22566040
[TBL] [Abstract][Full Text] [Related]
40. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
Yoshida S; Nakagomi K; Goto S; Futatsubashi M; Torizuka T
Urol Int; 2005; 74(3):214-20. PubMed ID: 15812206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]